Wearable Injector Delivers Drugs Subcutaneously
By HospiMedica International staff writers Posted on 31 Dec 2020 |
Image: The BD Libertas Wearable Injector (Photo courtesy of BD)
A novel adhesive subcutaneous injector delivers large volume drugs to support life cycle management of biological therapies.
The BD (Franklin Lakes, NJ, USA) BD Libertas Wearable Injector is a drug delivery system, currently in final phases of development, designed to deliver drugs with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations, facilitating the migration from intravenous (IV) to subcutaneous routes of administration. The device delivers therapeutic drugs using a customizable flow rate adjusted to drug viscosity and therapy needs, providing slow drug infusion subcutaneously over the desired period of time, ranging from a few seconds to several minutes. Optional smart functionality enables connectivity to the healthcare network.
A recent clinical trial to evaluate the performance of the 5 mL BD Libertas device in humans, which monitored effects such as tissue responses, skin reactivity, and patient acceptance, confirmed that the device delivered within an acceptable time period 5 mL of 8 cP subcutaneous injections to the abdomen and thigh, regardless of subject age, gender, or body mass index (BMI), and both with or without patient movement. No severe wheal, erythema, or bleeding was observed, and no unacceptable pain was noted at 24 hours post-injection.
“These results show that BD Libertas Wearable Injector effectively delivers dose volumes up to 5 mL subcutaneously, and may be leveraged by our pharmaceutical partners as a reliable platform for large volume delivery,” said Eric Borin, worldwide president of BD Pharmaceutical Systems. “BD is committed to working with our customers and the broader pharmaceutical market to meet their needs by enabling an expanded drug delivery design space.”
Subcutaneous injections are highly effective in administering medications such as insulin, morphine, diacetylmorphine, and goserelin. As subcutaneous tissue has few blood vessels, the drugs are injected as a bolus, undergoing subsequent slow, sustained rates of absorption. It is a slower (but less painful) route than intramuscular injections, especially for viscous drugs, but still faster than intradermal injections.
Related Links:
BD
The BD (Franklin Lakes, NJ, USA) BD Libertas Wearable Injector is a drug delivery system, currently in final phases of development, designed to deliver drugs with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations, facilitating the migration from intravenous (IV) to subcutaneous routes of administration. The device delivers therapeutic drugs using a customizable flow rate adjusted to drug viscosity and therapy needs, providing slow drug infusion subcutaneously over the desired period of time, ranging from a few seconds to several minutes. Optional smart functionality enables connectivity to the healthcare network.
A recent clinical trial to evaluate the performance of the 5 mL BD Libertas device in humans, which monitored effects such as tissue responses, skin reactivity, and patient acceptance, confirmed that the device delivered within an acceptable time period 5 mL of 8 cP subcutaneous injections to the abdomen and thigh, regardless of subject age, gender, or body mass index (BMI), and both with or without patient movement. No severe wheal, erythema, or bleeding was observed, and no unacceptable pain was noted at 24 hours post-injection.
“These results show that BD Libertas Wearable Injector effectively delivers dose volumes up to 5 mL subcutaneously, and may be leveraged by our pharmaceutical partners as a reliable platform for large volume delivery,” said Eric Borin, worldwide president of BD Pharmaceutical Systems. “BD is committed to working with our customers and the broader pharmaceutical market to meet their needs by enabling an expanded drug delivery design space.”
Subcutaneous injections are highly effective in administering medications such as insulin, morphine, diacetylmorphine, and goserelin. As subcutaneous tissue has few blood vessels, the drugs are injected as a bolus, undergoing subsequent slow, sustained rates of absorption. It is a slower (but less painful) route than intramuscular injections, especially for viscous drugs, but still faster than intradermal injections.
Related Links:
BD
Latest Patient Care News
- First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
- Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization
- Game-Changing Innovation in Surgical Instrument Sterilization Significantly Improves OR Throughput
- Next Gen ICU Bed to Help Address Complex Critical Care Needs
- Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape
- Clean Hospitals Can Reduce Antibiotic Resistance, Save Lives
- Smart Hospital Beds Improve Accuracy of Medical Diagnosis
- New Fast Endoscope Drying System Improves Productivity and Traceability
- World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance
- Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER
- Portable Clinical Scale with Remote Indicator Allows for Flexible Patient Weighing Use
- Innovative and Highly Customizable Medical Carts Offer Unlimited Configuration Possibilities
- Biomolecular Wound Healing Film Adheres to Sensitive Tissue and Releases Active Ingredients
- Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases
- Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest
- World's First AI-Ready Infrasound Stethoscope Listens to Bodily Sounds Not Audible to Human Ear